Customer stories from teams like yours, how Sleuth compares with the tools you use now, and Sleuth’s news and perspectives.

The strategy team answers its questions from one peer database, each answer traced to its source.

Each team brings its own question, and its time goes into the decision instead of the data gathering.

The team calls each sponsor before it picks a diagnostic partner, and opens on that sponsor’s own programs.

Before any trial, the team knew the bar was keeping patients on the drug.

A health-tech company’s hospitals see what’s coming every week, and no one on its team maintains the data.
Sleuth provides a confidence score for every value, so you know which to trust and which to review. Pencil Biosciences, a seed-stage gene-editing company, could potentially aim its platform at many diseases. With a raise coming up, it needed to select one lead program it could defend to investors.
Sleuth Studio lets one person do deep analysis and triage across a first-in-class pipeline. Juvena Therapeutics’ discovery work turns up targets across hundreds of indications, and co-founder and CSO Jeremy O’Connell researches each new target in Studio: the biology behind it, who else is drugging it, and how fast a trial could show it works.
Sleuth builds a dataset to your spec, checks it, and delivers it weekly. This one helps a health-tech company show hospitals what they need to prepare for new, advanced therapies.
Sleuth shows companies that sell to pharma which drug developers to reach, and when, from a live view of the market. One of the world’s largest oncology diagnostics companies used Studio to map every program in four newer kinds of cancer drug, see which patients the late-stage trials will add, and find the sponsors whose partner decisions are coming up.
Sleuth is market intelligence infrastructure for whole pharma teams. At one top-10 pharma, five teams, from business development to R&D, bring their hardest questions to Studio and get back answers that were previously buried in the data.
Sleuth shows founders what has failed in their field and why, so they can choose where to start. Suraj Pavagada was developing a new way to detect liver injury as a Stanford researcher, with no commercial team and investor meetings weeks away. Sleuth’s analysts reviewed ten years of liver-safety setbacks and surfaced a promising opportunity in about a week.
Biotechs rarely have too few indication options. In this post, we walk through a funnel for making defensible cuts, from hundreds of candidates to one lead indication.
The competitive landscape should drive every decision an early biotech makes. In this post, we walk through how to build a fundraise-ready competitive landscape.
Compounding intelligence is not just using AI to make outputs - it's building a system in which every piece of work improves the next decision.
AI has removed the constraints that forced every team to interrogate the world through the same datasets.
Sleuth shows you the bar your program has to clear, in trials and everyday care. LionBio was developing a GLP-1 nasal spray, and CEO Robin Guo expected it to cause less nausea than weekly injections. Sleuth’s analysts compared how long patients stay on GLP-1s, in trials and in everyday care. The bar turned out to be keeping patients on the drug.
One insight stands out in how top-25 Pharma companies are bringing AI into their organizations: intentionality.
AI is collapsing the cost of producing biopharma intelligence. The bottleneck has shifted from building the output to verifying it, defending it, and acting on it.
Sleuth data featured in The Wall Street Journal
What a 12,000-indication landscape taught us about building multi-agent biopharma analysis systems
A look under the hood at the infrastructure powering Sleuth: a continuously maintained knowledge graph of the biopharma landscape, structured through extraction and validation, designed to produce traceable, decision-grade analysis.
Sleuth Studio lets small teams screen indications on their own criteria and refine the analysis as questions change. Epana Bio used it to decide which indications to pursue first, one of the highest-stakes calls an early biotech makes.
Sleuth Concierge delivers consulting-grade work in a fraction of the time and cost, and the work doesn’t go stale after the handoff. At Daiichi Sankyo, each new strategy question builds on the same peer database.
Sleuth Insights launched from stealth with $8M in seed funding led by Bison Ventures to modernize how biopharma strategy, BD and competitive intelligence teams make decisions.
Sleuth's founder and CEO on what the team built, why it matters now, and what it means for biopharma intelligence teams.
Biopharma analyses tailored to your questions, grounded in connected evidence, ready for executive conversations. Sleuth Studio in 90 seconds.
Today we're opening up the intelligence infrastructure we've spent two years running underneath pharma and biotech engagements. A look at how Sleuth Studio works, why connected data changes what AI can do, and what it means for high-stakes decisions.
Most biopharma intelligence teams are running two races at once: the sprint to get smart fast, and the marathon of keeping the competitive picture current. In theory they should compound. In practice they never do. A look at why, and what needs to change.